KIR3DL1 and neoplasm: In NSCLC patients, tumor-infiltrating NK cells exhibit significantly elevated PD-1 expression, and these PD-1-positive NK cells concurrently coexpress multiple inhibitory receptors, including TIM-3, TIGIT, KIR2DL3, and KIR3DL1, resulting in compromised NK cell functionality.